[
  {
    "ts": null,
    "headline": "PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co",
    "summary": "Insights from the Fourth Quarter 2025 13F Filing",
    "url": "https://finnhub.io/api/news?id=140a86a42418b7a9e8a0aec8ed9cb0941595dbf137d681aa4b51a7c1389a00f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770850820,
      "headline": "PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co",
      "id": 139050526,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insights from the Fourth Quarter 2025 13F Filing",
      "url": "https://finnhub.io/api/news?id=140a86a42418b7a9e8a0aec8ed9cb0941595dbf137d681aa4b51a7c1389a00f4"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Eli Lilly, Marriott & Fortinet",
    "summary": "Eli Lilly's Q4 beat and soaring GLP-1 demand lead top analyst picks, alongside fresh insights on Marriott and Fortinet's latest results.",
    "url": "https://finnhub.io/api/news?id=a85fd110ad03a6de04dd03e3d7cb02c215f5e65f267e64daf03f2938245aa07c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770844440,
      "headline": "Top Analyst Reports for Eli Lilly, Marriott & Fortinet",
      "id": 139050527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Q4 beat and soaring GLP-1 demand lead top analyst picks, alongside fresh insights on Marriott and Fortinet's latest results.",
      "url": "https://finnhub.io/api/news?id=a85fd110ad03a6de04dd03e3d7cb02c215f5e65f267e64daf03f2938245aa07c"
    }
  },
  {
    "ts": null,
    "headline": "Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment. Eli Lilly and Company (NYSE:LLY)’s shares have gained roughly 70% in the past […]",
    "url": "https://finnhub.io/api/news?id=631fd83566de923291fc78e8535f1532a5dedbf71813e957e68474fc1e06fafe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770837988,
      "headline": "Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment",
      "id": 139048023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment. Eli Lilly and Company (NYSE:LLY)’s shares have gained roughly 70% in the past […]",
      "url": "https://finnhub.io/api/news?id=631fd83566de923291fc78e8535f1532a5dedbf71813e957e68474fc1e06fafe"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A Great Opportunity Post Earnings",
    "summary": "Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=8e3931c8fec43fa237de8abc9d559f46a2d1744edad4b12f1bedbfeea684327a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770833286,
      "headline": "Pfizer: A Great Opportunity Post Earnings",
      "id": 139050218,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=8e3931c8fec43fa237de8abc9d559f46a2d1744edad4b12f1bedbfeea684327a"
    }
  },
  {
    "ts": null,
    "headline": "Pharma companies left out of Trump's drug-pricing deals look for way in",
    "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
    "url": "https://finnhub.io/api/news?id=76636b34822603519183bdedc54a04d72ac40c8343f83bf7b8ba9046f79f10d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770832672,
      "headline": "Pharma companies left out of Trump's drug-pricing deals look for way in",
      "id": 139047279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
      "url": "https://finnhub.io/api/news?id=76636b34822603519183bdedc54a04d72ac40c8343f83bf7b8ba9046f79f10d1"
    }
  },
  {
    "ts": null,
    "headline": "'Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials' - Bloomberg",
    "summary": "https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials",
    "url": "https://finnhub.io/api/news?id=b0fb2e50285236c4fda31b69f5dfbff7c9e555c7bc068e76c0b0590dd3e21ce9",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828094,
      "headline": "'Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials' - Bloomberg",
      "id": 139057837,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials",
      "url": "https://finnhub.io/api/news?id=b0fb2e50285236c4fda31b69f5dfbff7c9e555c7bc068e76c0b0590dd3e21ce9"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Buy Eli Lilly Stock",
    "summary": "The healthcare leader looks increasingly unstoppable.",
    "url": "https://finnhub.io/api/news?id=6d61664559e63d63b3118de010ce4afa53fe3c905ffdc81c889b32846571c16b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770827700,
      "headline": "3 Reasons to Buy Eli Lilly Stock",
      "id": 139046343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare leader looks increasingly unstoppable.",
      "url": "https://finnhub.io/api/news?id=6d61664559e63d63b3118de010ce4afa53fe3c905ffdc81c889b32846571c16b"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
    "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=e454174031cbd5f147537242509ca8f4f827acefbc8ceb6c7d19ed9073317485",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770824100,
      "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
      "id": 139044984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=e454174031cbd5f147537242509ca8f4f827acefbc8ceb6c7d19ed9073317485"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start",
    "summary": "The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.",
    "url": "https://finnhub.io/api/news?id=d0d79a23ff313ad6751b9b4bb908cb78f56af589e2e5236d5c4137d1d6b48ceb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770822184,
      "headline": "Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start  ",
      "id": 139064734,
      "image": "https://image.cnbcfm.com/api/v1/image/108245148-1766497149406-gettyimages-2245790195-AFP_83TG86Z.jpeg?v=1770838165&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share. ",
      "url": "https://finnhub.io/api/news?id=d0d79a23ff313ad6751b9b4bb908cb78f56af589e2e5236d5c4137d1d6b48ceb"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?",
    "summary": "NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.",
    "url": "https://finnhub.io/api/news?id=875972ffe121069a647a20a8651d5d5da1f83296748fb4ff4e2e2c018d612e76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770821640,
      "headline": "Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?",
      "id": 139046411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.",
      "url": "https://finnhub.io/api/news?id=875972ffe121069a647a20a8651d5d5da1f83296748fb4ff4e2e2c018d612e76"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs",
    "summary": "Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.",
    "url": "https://finnhub.io/api/news?id=87f01de50097ad06844b767e9a5db41648c51dd209cf897708eafded5391856c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809109,
      "headline": "Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs",
      "id": 139045938,
      "image": "https://image.cnbcfm.com/api/v1/image/108264491-1770826608786-MD-2.png?v=1770826644&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.",
      "url": "https://finnhub.io/api/news?id=87f01de50097ad06844b767e9a5db41648c51dd209cf897708eafded5391856c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
    "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
    "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770804000,
      "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
      "id": 139044801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
      "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f"
    }
  },
  {
    "ts": null,
    "headline": "Taking the new Wegovy pill every day is really complicated. Will patients stick with it?",
    "summary": "Taking the new Wegovy pill every day is really complicated. Will patients stick with it?",
    "url": "https://finnhub.io/api/news?id=8595b5d6f3169f4dd400e83579c8ccdbb658fa8b91ae9650f737d6fee014ca92",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770800340,
      "headline": "Taking the new Wegovy pill every day is really complicated. Will patients stick with it?",
      "id": 139058693,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Taking the new Wegovy pill every day is really complicated. Will patients stick with it?",
      "url": "https://finnhub.io/api/news?id=8595b5d6f3169f4dd400e83579c8ccdbb658fa8b91ae9650f737d6fee014ca92"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
    "summary": "This stock has been known to soar after good news.",
    "url": "https://finnhub.io/api/news?id=449f2fba62b30440a7ed69a0d2a6aa7beb759d3a39bd026d0f403ba0eeeab269",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770791700,
      "headline": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
      "id": 139041030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This stock has been known to soar after good news.",
      "url": "https://finnhub.io/api/news?id=449f2fba62b30440a7ed69a0d2a6aa7beb759d3a39bd026d0f403ba0eeeab269"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
    "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
    "url": "https://finnhub.io/api/news?id=91403d4d4cc56bd4e3ce4450ef168b3771ac8f3f7cc48f2c4ad1afdec1dde584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788498,
      "headline": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
      "id": 139042246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
      "url": "https://finnhub.io/api/news?id=91403d4d4cc56bd4e3ce4450ef168b3771ac8f3f7cc48f2c4ad1afdec1dde584"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
    "url": "https://finnhub.io/api/news?id=e61bc646efbda77ca763b03ad544fc8401813b28d390b792ca87fc4a797f1691",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770784489,
      "headline": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
      "id": 139039335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
      "url": "https://finnhub.io/api/news?id=e61bc646efbda77ca763b03ad544fc8401813b28d390b792ca87fc4a797f1691"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "summary": "Could these two companies be biotech giants in the making?",
    "url": "https://finnhub.io/api/news?id=d7a40f61131bfb68fe11e2d7641dbfc3bf4a3f1cbc16fab742fd9918c593f979",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770773460,
      "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
      "id": 139038265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Could these two companies be biotech giants in the making?",
      "url": "https://finnhub.io/api/news?id=d7a40f61131bfb68fe11e2d7641dbfc3bf4a3f1cbc16fab742fd9918c593f979"
    }
  }
]